^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    16h
    PIPSeN: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties
    Enrollment change • Trial termination • Platinum sensitive
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation
    |
    Lynparza (olaparib)
    1d
    CRUKD/20/001: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Mar 2029 --> Oct 2026
    Trial completion date • Checkpoint inhibition • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    4d
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    4d
    A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Dec 2025
    Trial primary completion date • IO biomarker
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab)
    4d
    ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. (PubMed, J Thorac Oncol)
    NSCLCs harboring ECD-ERBB2 mutations are associated with a unique clinico-genomic phenotype and improved outcomes with first-line chemoimmunotherapy. These findings have implications for optimizing treatment strategies in this disease.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RBM10 (RNA Binding Motif Protein 10)
    |
    KRAS mutation • EGFR mutation • PIK3CA mutation • HER-2 mutation • STK11 mutation • KEAP1 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Hernexeos (zongertinib) • Hyrnuo (sevabertinib)
    6d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=387, Recruiting, Pfizer
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    6d
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=59, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    6d
    Real-life first-line systemic treatments for metastatic non-small cell lung cancer (mNSCLC) - Data from the KBP-2020-CPHG cohort (PubMed, Bull Cancer)
    The use of immunotherapy in real life in 2020 in France shows an apparent gap with national guidelines that is more marked in cases of squamous cell NSCLC or with PD-L1 expression<50% with less exposure of patients to the immunotherapy-chemotherapy combination compared to current recommendations. This gap could be partly explained by the progressive reimbursement schedule of pembrolizumab and by other factors not documented in KBP-2020-CPHG.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab)
    8d
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | N=49 --> 180
    Enrollment change • Trial initiation date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    8d
    Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Radiopharm Theranostics, Ltd | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    9d
    SGNCEA5C-001: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=165, Suspended, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Suspended
    Trial suspension
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    9d
    PERSEE: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (clinicaltrials.gov)
    P3, N=349, Completed, University Hospital, Brest | Not yet recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel